Top-line data from the Phase III LAGOON study leave Zepzelca without confirmatory data for second-line treatment of small cell lung cancer, but first-line maintenance therapy remains the focus.
Top-line data from the Phase III LAGOON study leave Zepzelca without confirmatory data for second-line treatment of small cell lung cancer, but first-line maintenance therapy remains the focus.